Back to Browse Journals » Clinical Ophthalmology » Volume 7

Tafluprost once daily for treatment of elevated intraocular pressure in patients with open-angle glaucoma

Authors Liu Y, Mao W

Received 11 October 2012

Accepted for publication 20 November 2012

Published 21 December 2012 Volume 2013:7 Pages 7—14

DOI http://dx.doi.org/10.2147/OPTH.S30951

Checked for plagiarism Yes

Review by Single-blind

Peer reviewer comments 3

Yang Liu, Weiming Mao

Department of Cell Biology and Anatomy, North Texas Eye Research Institute, University of North Texas Health Science Center, Fort Worth, TX

Abstract: Glaucoma is a leading cause of visual loss worldwide. Current antiglaucoma therapy focuses on lowering intraocular pressure to a safe level. In recent years, prostaglandin analogs have become the first-line agents for treating open angle glaucoma. Tafluprost, which was first reported in 2003, is a novel prostaglandin analog, and has been shown to be a potent ocular hypotensive agent in a number of preclinical and clinical studies. Also, its unique preservative-free formulation helps to decrease preservative-associated ocular disorders and improve patient compliance. In this review, studies from 2003 to 2012 focusing on the structure, metabolism, efficacy, and safety of tafluprost are summarized. These studies suggested that application of tafluprost once daily is a safe and effective treatment for patients with open angle glaucoma.

Keywords: tafluprost, prostaglandin analog, glaucoma, intraocular pressure, preservative-free formulation

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF] View Full Text [HTML] 

 

Readers of this article also read:

Spontaneous resolution of subfoveal perfluorocarbon

Oellers P, Charkoudian LD, Hahn P

Clinical Ophthalmology 2015, 9:517-519

Published Date: 19 March 2015

A tool for assessing the feasibility of comparative effectiveness research

Walker AM, Patrick AR, Lauer MS, Hornbrook MC, Marin MG, Platt R, Roger VL, Stang P, Schneeweiss S

Comparative Effectiveness Research 2013, 3:11-20

Published Date: 30 January 2013

Simple room-temperature preparation of high-yield large-area graphene oxide

Huang NM, Lim HN, Chia CH, Yarmo MA, Muhamad MR

International Journal of Nanomedicine 2011, 6:3443-3448

Published Date: 19 December 2011

Kinetics of central macular thickness reduction in patients with macular edema after intravitreal drug therapy

He L, Chan A, Leng T, Blumenkranz MS

Clinical Ophthalmology 2011, 5:1751-1758

Published Date: 9 December 2011

Subtle cytotoxicity and genotoxicity differences in superparamagnetic iron oxide nanoparticles coated with various functional groups

Hong SC, Lee JH, Lee J, Kim HY, Park JY, Cho J, Lee J, Han DW

International Journal of Nanomedicine 2011, 6:3219-3231

Published Date: 7 December 2011

Validation of four automatic devices for self-measurement of blood pressure according to the international protocol of the European Society of Hypertension

Topouchian J, Agnoletti D, Blacher J, Youssef A, Ibanez I, Khabouth J, Khawaja S, Beaino L, Asmar R

Vascular Health and Risk Management 2011, 7:709-717

Published Date: 30 November 2011

Progress in antiretroviral drug delivery using nanotechnology

Rama Mallipeddi, Lisa Cencia Rohan

International Journal of Nanomedicine 2010, 5:533-547

Published Date: 22 July 2010

In vitro and in vivo effects of polyethylene glycol (PEG)-modified lipid in DOTAP/cholesterol-mediated gene transfection

Torben Gjetting, Nicolai Skovbjerg Arildsen, Camilla Laulund, et al

International Journal of Nanomedicine 2010, 5:371-383

Published Date: 25 May 2010

Transdermal hormone therapy and bone health

Lee P Shulman

Clinical Interventions in Aging 2008, 3:51-54

Published Date: 7 March 2008